Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice

The Alzheimer's Association Research Roundtable (AARR) convened leaders from industry, academia, and government, to review the <i>Revised Criteria for Diagnosis and Staging of AD: AA Workgroup</i>, and gather industry perspectives and feedback on these revised criteria before its publication.The newly proposed revised criteria for diagnosis and staging of Alzheimer's disease (AD) by the AA's Workgroup represent a significant milestone, offering objective measures for the biological and staging of AD and bridging the gap between research and clinical care.Improving the availability and accuracy of biomarkers, especially blood-based biomarkers (BBMs) is expected to improve clinical research and enhance the applicability of these criteria in clinical practice.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia Translational Research & Clinical Interventions
Published
2024-10-01
DOI
https://doi.org/10.1002/trc2.70013
Citations
7
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
2.70
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice

Hans J. Moebius, Simin Mahinrad, Clifford R. Jack, Erin Doty et al.
7 citations
Alzheimer s & Dementia Translational Research & Clinical Interventions
Dementia and Cognitive Impairment Research
2.70
article

Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice

Hans J. Moebius, Simin Mahinrad, Clifford R. Jack, Erin Doty, Kristin R. Wildsmith, Kaycee M. Sink, Charlotte T. Hansen, Christopher J. Weber, Philip H. Montenigro, Samantha C. Burnham, Eric Siemers, Leslie M. Shaw, Marı́a C. Carrillo, Ana Graf
article en
7 citations

Abstract

The Alzheimer's Association Research Roundtable (AARR) convened leaders from industry, academia, and government, to review the <i>Revised Criteria for Diagnosis and Staging of AD: AA Workgroup</i>, and gather industry perspectives and feedback on these revised criteria before its publication.The newly proposed revised criteria for diagnosis and staging of Alzheimer's disease (AD) by the AA's Workgroup represent a significant milestone, offering objective measures for the biological and staging of AD and bridging the gap between research and clinical care.Improving the availability and accuracy of biomarkers, especially blood-based biomarkers (BBMs) is expected to improve clinical research and enhance the applicability of these criteria in clinical practice.

Alzheimer s & Dementia Translational Research & Clinical InterventionsVol. 10(4)
Alzheimer's Association (US), Novartis (Switzerland) (CH), Mayo Clinic (US), Eli Lilly (United States) (US), Novo Nordisk (Denmark) (DK), Athira Pharma (United States) (US), Eisai (United States) (US), Acumen Pharmaceuticals (United States) (US), University of Pennsylvania (US)
Openalex Percentile: Top 9%
Dementia and Cognitive Impairment Research
2.70
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.